New Treatment for Ovarian Cancer Shows Promise
Source: Emily Bodnar  (3/30/23)
Additional trial data also show efficacy of this investigative combination treatment in a difficult to treat patient population, noted an H.C. Wainwright & Co. report. More >

Telehealth Co. Signs Largest Client Yet
Source: Streetwise Reports  (3/30/23)
Onboarding will begin in April for the healthcare system that has more than 1,200 care centers in seven states. More >

Coverage Launched on Drug Co. With 140% Upside
Source: Stefan Quenneville  (3/29/23)
The Canadian specialty pharma, with a proven track record of in-licensing and acquiring late-stage assets, is "poised to grow meaningfully in the coming years," noted an Echelon Capital Markets report. More >

Trial of New Ophthalmic Drug Now Enrolled
Source: Dr. Yi Chen  (3/29/23)
More than the target number of patients was enrolled in this Phase 2 study of an investigative treatment for a serious eye disease, noted an H.C. Wainwright & Co. report. More >

FDA Approval of New Gout Drug Likely, Analyst Says
Source: Yun Zhong  (3/27/23)
Despite a competitor already on the market, the commercial opportunity for this particular treatment is strong, given its advantages, noted a BTIG report. More >

Biotech Improves Efficiency of Its New Immunotherapy
Source: Dr. Jonathan Aschoff  (3/22/23)
The enhancements the company made to its investigative therapy that uses a patient's own immune cells were independently validated, noted a ROTH research report. More >

Former NFL Safety Director Joins Neurotherapy Firm Advisory Board
Source: Streetwise Reports  (3/21/23)
Treating traumatic brain injury with alternative pharmaceuticals is delicate work. Now one Canadian firm has enlisted the help of former National Football League Neurological Player Care Safety Director Dr. David Brody. More >

Coverage Launched on Canadian Specialty Pharma Co.
Source: Stefan Quenneville  (3/15/23)
This company can further grow its product portfolio and revenues and, thus, boost its operating leverage, but these capabilities "remain underappreciated by investors," noted an Echelon Capital Markets report. More >

Telemedicine Co. Sees Record Revenues on Software, Services Sales
Source: Streetwise Reports  (3/13/23)
Reliq Health Technologies Inc. reports that software and services revenue continues to increase, leading to record cash intake for the quarter that ended Dec. 31, 2022. More >

Blockchain Co. Launches Digital Coupon Consumer App
Source: Streetwise Reports  (3/8/23)
Global Compliance Applications Corp. is launching a new app that will enable consumers to receive and share digital token coupons and store them in digital wallets. More >

New Skin Gene Therapy Gets PDUFA Date
Source: Dr. Joseph Pantginis  (3/1/23)
The future of this investigational treatment for dystrophic epidermolysis bullosa looks positive, with full approval and subsequent successful commercial launch expected, noted an H.C. Wainwright & Co. report. More >

Novel Therapy Corp Captures More of US Licensing Market, First EU Segment
Source: Streetwise Reports  (2/28/23)
White-label reselling of proven therapeutic compounds and concepts to existing, branded providers offers research companies a way to capture market share without marketing expenses – or other customer-facing costs. Awakn Life Sciences Corp., already a marquee name in rehabilitation clinics across Europe, is also rapidly engaging in this lucrative secondary profit stream. More >

AI-Infused Telehealth Platform Absorbs New Patients
Source: Streetwise Reports  (2/22/23)
Telemedicine company Reliq Health Technologies Inc., which uses artificial intelligence in its software's algorithms, has gained six new contracts and more than 3,000 new patients. More >

Biotech Co. Initiates Feasibility Study
Source: Streetwise Reports  (2/9/23)
This morning Awakn Life Sciences announced it had initiated a feasibility study of MDMA leveraging Catalent's proprietary Zydis ODT fast dissolve technology. Read more to learn what this means for the company, why this may be needed, and what experts are saying about Awakn.  More >

Addiction Therapy Company Secures Major UK Endorsement
Source: Streetwise Reports  (2/7/23)
Pharmaceutical powerhouse Awakn has been awarded Innovative Licensing and Access Pathway (ILAP) access to UK markets. This classification, equivalent to FDA Breakthrough Therapy designation in the U.S., allows the company to expedite development growth in the region. More >

New Drug for Hearing Loss Approved for Clinical Trials
Source: Dr. Joseph Pantginis  (1/30/23)
Plans call for an initial clinical trial to start in H1/23 in both the U.S. and the United Kingdom, where the biopharma recently received approval to proceed, noted an H.C. Wainwright & Co. report. More >

Biopharma Gains Another Shot on Goal With IND Approval
Source: Edward White   (1/26/23)
The firm's CD19- and CD3-targeting monoclonal antibody is now cleared for evaluation in a Phase I clinical trial, noted an H.C. Wainwright & Co. report. More >

Former Investment Officer of One of the World's Largest Sovereign Wealth Funds Shares His Current Focus
Source: Streetwise Reports  (1/25/23)
Streetwise Reports sat down with Øyvind Schanke, the chief investment officer of TD Veen and the former investment officer of one of the world's largest sovereign wealth funds as he shares his current focus. More >

Med Tech Co. Well-Poised for Revenue Growth This Year
Source: Swayampakula Ramakanth  (1/25/23)
New revenue sources already in place are expected to boost cash flow 72% over the next 12 months, noted an H.C. Wainwright & Co. report. More >

Biopharma Creating COVID Drug Gets US$8.2M From the DOD
Source: Edward White  (1/24/23)
This tranche, other cash and cash equivalents, and current cash flow are sufficient to get the developer of immunotherapeutics through 2023, noted an H.C. Wainwright & Co. report. More >

Biotech's Novel Thin Formulation Improves Veteran-Aiding Treatment
Source: Streetwise Reports  (1/24/23)
Awakn Life Sciences announced further details regarding its August 2022 announcement that it had "signed a twelve-month option agreement with a leading drug development, manufacturing, and delivery systems company to in-license a proprietary formulation and route of administration for ketamine." Read to learn more about this announcement, the benefits of this treatment, and what analysts and experts are saying about the company. More >

Exploring Why The Economist Named this Biotech 'One To watch' in 2023
Source: Streetwise Reports  (1/23/23)
As more researchers delve into the medicinal potentials of once-verboten compounds, forward-thinking companies like Awakn Life Sciences Corp. are leading the charge to map their most useful aspects and open access for people who need help now. Read more to learn what catalysts Awakn has in store and why The Economist touched on this treatment as one of their top stories of 2023. More >

Telehealth Co. Expects More Growth in 2023
Source: Streetwise Reports  (1/20/23)
Officials at telemedicine company Reliq Health Technologies say they expect to accelerate growth "significantly" in 2023, which could lead to a share buyback program. More >

Biopharma Co.'s Burn Tissue Removal Product Approved
Source: Swayampakula Ramakanth  (1/4/23)
Because of the green light from the U.S. Food and Drug Administration, H.C. Wainwright & Co. raised its target price on the developer of this drug, according to a recent report. More >

Which Precious Metal Has Chen Excited for 2023?
Source: Streetwise Reports  (12/28/22)
It's valued the world over as a precious metal, and now it's in demand for the green economy. Which element has asset manager Chen Lin looking forward to the New Year? More >